Summary & Overview
HCPCS Level II J2468: Palonosetron Injection, 25 micrograms
HCPCS Level II code J2468 denotes an injection of palonosetron hydrochloride (posfrea), 25 micrograms, an antiemetic used to prevent chemotherapy-induced nausea and vomiting. Nationally, accurate coding for this injectable therapy matters for oncology care coordination, appropriate drug utilization tracking, and payer adjudication for supportive cancer medications.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise view of the code’s clinical context and expected sites of service, as well as benchmarking and policy-relevant considerations that typically accompany analysis of HCPCS drug codes: reimbursement benchmarks, coverage policy variability across major payers, and coding practice implications for oncology infusion services.
This publication provides practical reference material for billing teams, practice managers, and policy analysts seeking to understand where J2468 fits in the drug coding landscape, what payers commonly address in coverage language for antiemetics, and which operational touchpoints—such as billing lines and infusion workflow—are most relevant. Data not available in the input.
Billing Code Overview
HCPCS Level II code J2468 represents an injection of palonosetron hydrochloride (posfrea), 25 micrograms. This drug is an antiemetic used to prevent chemotherapy-induced nausea and vomiting. The service type is injectable medication administration, and the typical site of service is outpatient infusion centers, hospital outpatient departments, and oncology clinics where chemotherapy and supportive medications are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient scheduled to receive moderately to highly emetogenic chemotherapy in the outpatient oncology infusion clinic. The patient has a prescription for palonosetron hydrochloride, J2468 (25 micrograms), to prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV). Before infusion, nursing verifies chemotherapy regimen, allergy history, current antiemetic medications, and vital signs. The pharmacist compounds or dispenses the single-dose injectable preparation per facility protocol. Nursing administers J2468 intravenously as a single bolus or slow push, usually immediately prior to chemotherapy start. Billing is submitted under the patient’s medical benefit with applicable modifiers documenting unusual circumstances (for example, JW if part of the drug was discarded). Typical sites of service are outpatient hospital infusion centers, physician office–based infusion suites, or freestanding oncology infusion centers. Common clinical workflow steps include medication order verification, documentation of administration in the electronic health record, monitoring for immediate hypersensitivity, and coordination with antiemetic regimen documentation in the chemotherapy plan.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |